. 2000 Apr;68(4):2215–2223. doi: 10.1128/iai.68.4.2215-2223.2000

TABLE 4.

Effect of Aotus sera on the inhibition of the secondary processing of MSP1 and its relationship between antibody response and protection

Vaccine^a	Aotus		MSP1 processing inhibition^c		IIF^d	Estimated ELISA titer^e
Vaccine^a	No.	Species^c	Assay 1	Assay 2	IIF^d	Estimated ELISA titer^e
yP30P2MSP1₁₉ FVO	1432^b	N	++(+)	++(+)	10⁶	35,610
	2096^b	N	+++	+++	10⁶	35,157
	2068^b	N	++	+++	10⁶	15,205
	2104^b	N	+++	+++	10⁶	58,155
	2084	N	+	++	10⁵	16,292
	2095^b	N	+/−	+/−	10⁶	2,407
	2532	V	+	++	10⁶	26,420
	2528	V	+	+	10⁵	16,000
yP30P2MSP1₁₉ 3D7	2062	N	++	+++	10⁶	19,499
	2110^b	N	++	++	10⁵	33,101
	2082	N	+++	+++	10⁶	26,978
	2119	N	+++	+++	10⁶	29,077
bGST-MSP1₁₉	1597A	N	+++	+++	10⁶	37,036
	2052	N	+++	+++	10⁶	59,859
TBV25H	2032	N	+/−	−	<10²	15
	2100	N	−	−	<10²	24
	2122	N	−	−	<10²	12
	2107	N			<10²	8

rMSP1₁₉ or control TBV25H vaccine was delivered in CFA. Sera used for these assays were taken on day 14 after the third immunization (the day of parasite challenge).

Self-cleared infection.

N, A. nancymai; V, A. vociferans. −, no detectable processing inhibition; +/−, just detectable processing inhibition; +, significant processing inhibition; ++, strong processing inhibition; +++, apparently complete processing inhibition; ++(+),

Endpoint IIF titer against the FVO strain of P. falciparum parasites.

Determined at A₄₁₀ of 0.5 using yMSP1₁₉ QKNG as capture antigen.